Sanofi’s RSV shot had a bumpy rollout, more popular than expected, WSJ says

This year, Sanofi released Beyfortus, a new shot to protect babies from the respiratory syncytial virus, RSV, but a bumpy rollout of the shot led to many having to hunt down doses for their children, especially parents with commercial insurance, Liz Whyte of The Wall Street Journal reports. Meanwhile, the government has hundreds of thousands of unused doses through a federal program meant for at-risk children. Sanofi underestimated the demand for the shot and the company is working to increase its supply for next RSV season.